×
About 1,433 results

ALLMedicine™ Systemic Mastocytosis Center

Research & Reviews  361 results

Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis.
https://doi.org/10.1182/blood.2021012694
Blood Henriques A, Muñoz-González JI et. al.

Sep 9th, 2021 - Circulating tumor mast cells (CTMC) have been identified in the blood of a small number of patients with advanced systemic mastocytosis (SM). However, limited data exists about their frequency and prognostic impact in patients with mast cell activ...

A novel anti-c-Kit antibody-drug conjugate to treat wild-type and activating-mutant c-K...
https://doi.org/10.1002/1878-0261.13084
Molecular Oncology; Kim JO, Kim KH et. al.

Aug 19th, 2021 - c-Kit overexpression and activating mutations, which are reported in various cancers, including gastrointestinal stromal tumor (GIST), small-cell lung cancer (SCLC), acute myeloid leukemia, acral melanoma, and systemic mastocytosis (SM), confer re...

Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressiv...
https://doi.org/10.1016/j.ymthe.2021.08.009
Molecular Therapy : the Journal of the American Society O... Snider DB, Arthur GK et. al.

Aug 10th, 2021 - Activating mutations in c-KIT are associated with the mast cell (MC) clonal disorders cutaneous mastocytosis and systemic mastocytosis and its variants, including aggressive systemic mastocytosis, MC leukemia, and MC sarcoma. Currently, therapies ...

Avapritinib for Systemic Mastocytosis.
https://doi.org/10.1080/17474086.2021.1959315
Expert Review of Hematology; Bose P, Verstovsek S

Jul 23rd, 2021 - Systemic mastocytosis (SM) is a rare myeloid neoplasm driven in ≈95% of cases by activating KIT mutations, usually D816V. SM can be indolent (ISM), smoldering (SSM) and advanced (AdvSM), the latter characterized by organ damage resulting from infi...

see more →

Guidelines  1 results

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.

Dec 14th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

see more →

Drugs  181 results see all →

News  30 results

Gene-targeting therapy shown to reduce mastocytosis symptoms
https://www.mdedge.com/familymedicine/article/219888/asthma/gene-targeting-therapy-shown-reduce-mastocytosis-symptoms?channel=39313
CHEST Physician; Richard Mark Kirkner

Mar 31st, 2020 - A small-molecule kinase inhibitor that targets a gene mutation complicit in systemic mastocytosis has been found to reduce symptoms by about 30%, according to early results of a clinical trial scheduled to be presented at the American Academy of A.

Inhibitor can improve symptoms of systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/190755/cythemias/inhibitor-can-improve-symptoms-systemic-mastocytosis?channel=50517
Jen Smith

Dec 8th, 2018 - Photo by Jen Smith Jason R. Gotlib, MD SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers.

A Case of Systemic Mastocytosis With Associated Clonal Hematological Non-Mast Cell Lineage Disease at VA Pittsburgh Healthcare System
https://www.mdedge.com/fedprac/avaho/article/174895/lymphoma-plasma-cell-disorders/case-systemic-mastocytosis-associated
Liman AD, Gandhi A et. al.

Sep 14th, 2018 - Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm that is caused by accumulation of abnormal mast cells in the bone marrow, liver, spleen, and skin. The KIT D816V mutation encodes a constitutively activated receptor tyrosine kina.

Avapritinib produces durable responses in SM
https://www.mdedge.com/hematology-oncology/article/184888/leukemia-myelodysplasia-transplantation/avapritinib-produces-durable
HT Staff

Jun 25th, 2018 - Photo from EHA Poster session at the 23rd Congress of the European Hematology Association (EHA) STOCKHOLM—The KIT/PDGFRA inhibitor avapritinib has produced durable responses in patients with systemic mastocytosis (SM). In the phase 1 EXPLORER tria.

Mast cell synovitis: potential target in RA?
https://www.mdedge.com/internalmedicine/article/159905/rheumatoid-arthritis/mast-cell-synovitis-potential-target-ra/page/0/1

Mar 2nd, 2018 - Moreover, four of the nine patients with persistent mast cell-rich synovitis after 6 months of synthetic DMARDs had synovial lymphoid aggregates of CD20-positive B cells and/or CD138-positive plasma cells; in contrast, none of the 11 synovial mast.

see more →